Nasus Pharma

About

Funding history · 1 round · $10.0M total

Headcount over time

Q&A

When did Nasus Pharma go public and how much capital was raised?

Nasus Pharma completed its Initial Public Offering (IPO) in August 2025, raising $10,000,000. The shares began trading on the NYSE American LLC exchange under the ticker symbol NSRX.

What was the valuation of Nasus Pharma at the time of its IPO?

At the time of its IPO in August 2025, Nasus Pharma had a valuation of $75,000,000.

What was the most recent funding event for Nasus Pharma?

In February 2026, Nasus Pharma closed a private placement, raising approximately $15,000,000. This funding is intended to advance their intranasal epinephrine product candidate, NS002, towards a pivotal study and NDA submission, and to expand their pipeline.

What is Nasus Pharma's primary focus in product development?

Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products to treat emergency medical conditions, such as anaphylaxis and opioid overdose, using its proprietary Nasax® powder-based intranasal (PBI) technology.

What significant regulatory approval did Nasus Pharma receive in November 2025?

In November 2025, Nasus Pharma received a No-Objection Letter from Health Canada, allowing the company to initiate its planned Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation for anaphylaxis treatment.

What are the key findings from the interim results of Nasus Pharma's Phase 2 clinical study for NS002?

In January 2026, Nasus Pharma announced positive interim results from its Phase 2 clinical study of NS002, showing faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to the EpiPen® autoinjector. 91% of participants administered NS002 reached the epinephrine plasma threshold at 5 minutes, compared to 67% with EpiPen®.

Which companies is Nasus Pharma collaborating with for the development and commercialization of NS002?

In October 2025, Nasus Pharma announced a strategic collaboration with Aptar France S.A.S. and AptarGroup, Inc. to support the clinical development and commercialization of its intranasal powder epinephrine product candidate, NS002.

Who was recently appointed to Nasus Pharma's leadership team?

In November 2025, Nasus Pharma appointed.

Team · 2

Dr. Dalia Megiddo

Founder · Co-founder

Udi Gilboa

Founder · Co-founder & Executive Chairman

Sectors & technology

Highlights

Tags